Shots:

• The US FDA has granted breakthrough device designation to the Revivent TC system using in LIVE procedures for excluding scar tissue on the left ventricle- resulting from a heart attack- allowing a healthy portion of the heart to function efficiently
•  The LIVE procedure involves the implantation of anchor pairs on the scar along the septum of the right ventricle and outer surface of the left ventricle- leading to remodeling of the heart to a more normal shape and size and reduces wall stress- thus improves blood flow throughout the body. LIVE process remodels the heart- regain its function & renew life
• Revivent TC System is less invasive therapy for the patients with ischemic HF- providing relief by reducing the volume of abnormally dilated heart and increases ejection fraction- will evaluate in an ALIVE study enrolling ~120 patients across the US. Revivent TC System has received CE mark & is commercially available in the EU

Click here to­ read full press release/ article | Ref: BioVentrix | Image: Cath Lab Digest